Equities research analysts expect Omnicell, Inc. (NASDAQ:OMCL) to post $199.37 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Omnicell’s earnings. The highest sales estimate is $200.14 million and the lowest is $198.75 million. Omnicell reported sales of $182.62 million during the same quarter last year, which indicates a positive year over year growth rate of 9.2%. The company is expected to announce its next earnings results on Thursday, April 25th.

On average, analysts expect that Omnicell will report full-year sales of $892.30 million for the current year, with estimates ranging from $890.58 million to $894.45 million. For the next fiscal year, analysts forecast that the firm will report sales of $969.77 million, with estimates ranging from $936.68 million to $990.33 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Omnicell.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 7th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.16. The business had revenue of $211.75 million during the quarter, compared to the consensus estimate of $215.41 million. Omnicell had a net margin of 4.79% and a return on equity of 9.31%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 EPS.

OMCL has been the topic of several recent analyst reports. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Monday. Oppenheimer raised their price target on shares of Omnicell to $86.00 and gave the stock an “outperform” rating in a report on Friday, December 7th. BidaskClub cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $70.00 target price on shares of Omnicell in a research report on Friday, February 8th. They noted that the move was a valuation call. Finally, Dougherty & Co lifted their price target on shares of Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $76.56.

Shares of OMCL stock traded down $0.22 during trading on Wednesday, reaching $79.75. 283,872 shares of the company’s stock traded hands, compared to its average volume of 351,647. Omnicell has a 1 year low of $41.59 and a 1 year high of $86.87. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $3.26 billion, a P/E ratio of 52.12, a PEG ratio of 3.72 and a beta of 1.25.

In other news, insider Peter J. Kuipers sold 24,504 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $83.97, for a total value of $2,057,600.88. Following the transaction, the insider now directly owns 64,618 shares in the company, valued at $5,425,973.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nhat H. Ngo sold 1,823 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $82.33, for a total transaction of $150,087.59. Following the completion of the transaction, the executive vice president now owns 37,569 shares in the company, valued at $3,093,055.77. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,630 shares of company stock worth $7,247,719. Company insiders own 3.71% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Geode Capital Management LLC grew its stake in Omnicell by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 442,184 shares of the company’s stock valued at $27,079,000 after acquiring an additional 32,512 shares during the period. Norges Bank purchased a new position in Omnicell in the 4th quarter valued at $12,125,000. O Brien Greene & Co. Inc purchased a new position in Omnicell in the 4th quarter valued at $374,000. Amalgamated Bank purchased a new position in Omnicell in the 4th quarter valued at $373,000. Finally, Millennium Management LLC lifted its holdings in Omnicell by 182.1% in the 4th quarter. Millennium Management LLC now owns 25,354 shares of the company’s stock valued at $1,553,000 after purchasing an additional 56,254 shares in the last quarter. Hedge funds and other institutional investors own 98.62% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.